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Abstract
Background: The dengue non-structural 3 (NS3) is a multifunctional protein, containing a serine-protease domain,
located at the N-terminal portion, and helicase, NTPase and RTPase domains present in the C-terminal region. This
protein is considered the main target for CD4+ and CD8+ T cell responses during dengue infection, which may be
involved in protection. However, few studies have been undertaken evaluating the use of this protein as a protective
antigen against dengue, as well as other flavivirus. In the present work we evaluated the potential of the NS3 (protease
domain) as a protective antigen by comparing the administration of a recombinant protein versus a DNA vaccine in
the mouse model.
Results: BALB/c mice were immunized with the recombinant protein NS3-DEN3 via intraperitoneal and with plasmid
pcDNA3/NS3-DEN3 intramuscularly and the immune response was evaluated. The activity of T lymphocytes was
analyzed by the MTT assay, and cells of mice immunized with the recombinant protein showed no activity when
stimulated with the homologous protein. However, cells from mice immunized with DNA, responded to stimulation
with the recombinant protein. When the expression (RT-PCR) and cytokine production (ELISA) was evaluated in the
splenocytes, different behavior depending on the type of immunization was observed, splenocytes of mice immunized
with the recombinant protein expressed cytokines such as IL-4, IL-10 and produced high concentrations of IL-1, IL-6
and TNFα. Splenocytes from mice immunized with DNA expressed IL-2 and IFNγ and did not produce IL-6. In addition,
immunization with the recombinant protein induced the production of antibodies that are detected up to a dilution 1:
3200 by ELISA and Western blot assays, however, the serum of mice immunized with DNA presented no detectable
antibody titers.
Conclusion: The results obtained in this study show that administration of pcDNA3/NS3-DEN3 induces a favorable
response in the activation of T lymphocytes with low production of specific antibodies against NS3-DEN3.
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Background
Dengue is the most prevalent arboviral disease world-
wide. The outcome of the infection is determined by
the interplay of viral and host factors. There are esti-
mated 390 million dengue infections per year world-
wide, of which 96 million manifest clinically with some
level of severity [1]. The etiological agent of dengue
disease is the Dengue virus (DENV) being the princi-
pal arthropod-borne viral pathogen affecting human
populations. It is an enveloped virus member of the
Flaviviridae family, containing a ~11 kb genome of
positive single-stranded RNA which encodes three
structural proteins (C, pr-M, E) and seven nonstruc-
tural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B,
NS5) [2]. Four serotypes of dengue virus (DENV-1,
DENV-2, DENV-3, and DENV-4) cause dengue fever
(DF) and more severe manifestations such as dengue
hemorrhagic fever (DHF) and dengue shock syndrome
(DSS) [3]. Currently, the infection caused by dengue
virus is classified into dengue with/without warning
signs and severe dengue [4].
Dengue virus NS3 is a multifunctional protein playing
a major role during viral replication. Both protease and
helicase domains of NS3 are interacting with human
and insect host proteins including innate immune com-
ponents of the host machinery [5]. The NS3 is a con-
served protein among the different dengue serotypes,
which elicits a strong cellular immune response after
viral infection in humans and animal models [6, 7].
Nevertheless, there are only few studies evaluating the
use of the NS3 protein as a protective antigen against
DENV [8], as well as other virus from the Flaviviridae
family [9]. In general, immunization with NS3 induced
little protection in different animal models [10]. Our
group has previously reported the expression of a fu-
sion protein derived from the N-terminal region of the
dengue virus NS3 protein for diagnostic use [11], how-
ever, the majority of T-cell epitopes are concentrated
within the NS3 protein, the main target for CD4+ and
CD8+ T cell response [6, 7, 11]. The role of T cells in
immunity against dengue infection has been extensively
reviewed [12, 13], the CD4+ T cell response contributes
to protection by instructing B cell responses against the
virus [14]. DNA vaccines are able to promote long-
lasting cellular immunity against some pathogens,
including flaviviruses [15]. Additionally, in contrast
vaccination with recombinant protein, DNA vaccin-
ation approach promotes in vivo expression of antigens,
as it originally occurs during the course of natural viral
infections. Finally, DNA vaccines lead to suitable post-
translational modifications and proper protein folding,
features that can directly influence the quality of the
elicited immunity [16–19]. Antigen expression in host
cells can induce complete and lasting immune response
including antibodies, although it is often weaker than
that available with recombinant vaccines, as well as a
strong and lasting activation of T helper cells and cyto-
toxic or cellular response [17, 20]. In this paper it was
compared the immune response from a recombinant
protein and a DNA vaccine derived from the NS3 pro-
tein (protease domain) in the mouse model.
Methods
Dengue virus and mice
Viral RNA of DEN3 (strain H87) was obtained by
extracting 2 mL of the clarified culture media with
1 mL of TRIzol LS Reagent (Invitrogen) according to
the manufacturer’s instructions and used as template
for the synthesis of a cDNA and obtain the PCR prod-
uct (590 pb) for the protease domain of NS3 protein ac-
cording to that reported previously [11]. Mice of the
BALB/c strain were purchased from CINVESTAV-IPN
(Mexico, DF). All mice were maintained according to
the recommendations of our Institutional Animal Care
and Use Committee.
Expression, Solubilization, and Purification of
GST-NS3DEN3
Competent Escherichia coli strain DH5-α cells were trans-
formed with the parental vector (pGEX-5X-1) and with
the recombinant expression vector (pGEX-NS3DEN3),
and were inoculated into LB media containing 100 mg/L
ampicillin (Sigma, St. Louis, MO, USA), and incubated at
37 °C overnight. Fresh LB media was incubated at 37 °C
with the overnight culture (1:100) to an OD600 = of 0.5,
and protein production was induced by addition of
isopropyl-β-D-thiogalactoside (IPTG) to a final concentra-
tion of 0.1 mM. After 2-h incubation, cells were harvested
and purification of expressed proteins was performed es-
sentially as described by López-Monteon et al. 2003 [17].
with the following modifications: Pellets were treated to
solubilize the inclusion bodies; briefly, the pellets were
washed twice with 50 mL of PBS (137 mM NaCl, 2.7 mM
KCl, 4.3 mM Na2HPO4 · 7H2O, and 1.4 mM KH2PO4,
pH 7.4), incubated at 37 °C under constant stirring for
20 min and centrifuged at 3046 × g at 4 °C for 10 min.
After that, pellets were suspended by vortexing with PBS
1X pH 7.4 containing 2 M urea, the sample was stirred
vigorously for 2 min, incubated at 37 °C under constant
stirring for 30 min, and subsequently, centrifuged at
3046 × g for 10 min. The supernatants obtained from the
solubilization of the inclusion bodies were dialyzed to re-
move urea. These supernatants were dialyzed against PBS
1X pH 7.4 overnight at 4 °C with constant stirring. The
supernatant containing solubilized fusion protein (GST-
NS3-DEN3) was mixed with glutathione-agarose beads
(sulfur linkage; Sigma). After absorption for 30 min, beads
were collected and washed by centrifugation. Either GST
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or GST-NS3-DEN3 were eluted by competition with free
glutathione (15 mM glutathione in 50 mM Tris-HCl
pH 8.0) and then acetone-precipitated.
Purification of plasmid DNA
DNA plasmids pcDNA3 and pcDNA3/NS3-DEN3 were
isolated from bacteria by alkaline lysis. Briefly, bacterial
pellets were resuspended in 100 μL (25 mM Tris-HCl
(pH 8.0), 10 mM EDTA (pH 8.0) and 50 mM sacchar-
ose) and repelleted. Alkaline lysis was performed by
overlaying the pellets with 200 μL (0.2 N NaOH, 1%
SDS), neutralization was achieved by adding 150 μL po-
tassium acetate (5 M). The supernatant was extracted
with phenol/chloroform, followed by ethanol precipita-
tion of plasmid DNA. The purified DNA was run on 1%
agarose gel in TAE buffer (45 mM Tris-acetic acid,
0.5 M EDTA, pH 8.0), and DNA bands were visualized
by ethidium bromide staining.
Cell treatment and transfection
HeLa cells were obtained from the American Type Cul-
ture Collection and were cultured in 1640 medium
(Gibco, Life technology, USA) supplemented with 10%
fetal bovine serum (Hyclone, Thermo Scientific, USA) in
a humidified incubator in 5% CO2 at 37 °C. For transfec-
tion of pcDNA and pcDNA3/NS3DEN3, 1 × 105 HeLa
cells were seeded on each well of 24-well plate. After
culturing for 24 h or adherent HeLa cells reached ap-
proximately 70% confluency, cells were transiently
transfected under optimized transfection conditions.
Briefly, 0.8 μg of plasmid DNA was diluted in 50 μL of
OptiPro™SFM, and mixed with 2.0 μL of Lipofectamine®
2000 CD (Lipofectamine, Invitrogen, USA) in 50 μL of
OptiPro™SFM and incubated for 20 min at room
temperature. The mixture was then added to the cells,
and incubated at 37 °C in a humidified atmosphere and
5% CO2 for further 72 h.
Immunization of mice with recombinant protein
and plasmid DNA
Female BALB/c mice (6- to 8-week old) were immu-
nized by the intraperitoneal route. The mice were im-
munized with one dose of 100 μg of GST-NS3-DEN3
and two more with 50 μg. First immunizations were
performed with the antigen emulsified in complete
Freund’s adjuvant (CFA), and re-immunizations at one-
week intervals were performed with incomplete
Freund’s adjuvant (Gibco-BRL, Grand Island, NY,
USA). The same schedule was used for control group
(n = 4), which received only GST plus adjuvant. At the
end of the immunization scheme, animals were bled to
obtain immune sera. On the other hand, DNA immuni-
zations were done twice at 2-week intervals in each
tibialis anterioris muscles with 50 μg of plasmids
(pcDNA/NS3-DEN3 or parental pcDNA3) dissolved in
50 μL of phosphate buffer saline (PBS) (100 μg/mouse)
(Fig. 1).
Proliferation assay
Spleens from normal and immunized BALB/c mice were
removed aseptically, dispersed into single-cell suspen-
sions, and erythrocytes removed by treating cell suspen-
sions with ACK buffer (150 mM NH4Cl, 1 mM KHCO3,
0.1 mM Na2EDTA pH 7.4) [21]. Splenocytes were resus-
pended in Dulbecco modified Eagle Medium (DMEM)
containing 10% heat inactivated FCS (Gibco, BRL), 100
U/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glu-
tamine, and 0.05 mM 2-β-Mercaptoethanol. Spleen cells
were cultured in 96-well flat-bottom plates at 4 × 105/well
and 37 °C under humidified atmosphere of 5% CO2.
Cultures were stimulated in triplicate with 4 μg/mL of
Concanavalin A (Con A, Sigma Chemical Co.), and
with the antigen (an optimal dose of 10 μg/mL and
50 μg/mL was used throughout the experiments) in a
total volume of 200 μL culture medium, at the end of
culture, cells were centrifuged at 120 × g and resus-
pended in 100 μL of fresh medium, subsequently it was
added 10 μL of the 12 mM MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] stock
solution (Vybrant®, Molecular Probes) to each well.
Include a negative control of 10 μl of the MTT stock
solution added to 100 μL of medium alone. The plate
was incubated at 37 °C for 4 h. At the end of the incu-
bation, 100 μL of the SDS-HCl solution were added to
each well and mixed thoroughly using the pipette and
the plate was incubated at 37 °C for 4–18 h in a hu-
midified chamber. Finally, samples were mixed using a
pipette and absorbance read at 570 nm in a microplate
reader (Multiskan EX, Thermo Electron Corporation).
RNA Isolation and RT-PCR
Total RNA from cells, cultured in 24-well plates with
different treatments for 48 h, was isolated using the TRI-
zol system (Life Technologies). One microgram of RNA
was reverse transcribed to cDNA with an oligonucleo-
tide (poly(dT)16) using the SuperScript II reverse tran-
scriptase (Life Technologies) and the cDNA used as a
template for PCR. PCR sequences and PCR conditions
used for amplification of GAPDH, IL-2 [22], IL-4, IL-10
and IFN-γ [23]: GAPDH (5′-GGT GAA GGT CGG
AGT CAA CGG-3′ and 5′-GGT CAT GAG TCC TTC
CAC GAT-3′), IL-2 (5′-GAC ACT TGT GCT CCT
TGT CA-3′ and 5′- TCA ATT CTG TGG CCT GCT
TG -3′), IL-4 (5′- ATG GGT CTC AAC CCC CAG
CTA GT -3′ and 5′- GCT CTT TAG GCT TTC CAG
GAA GTC - 3′), IL-10 (5′- CCT GGT AGA AGT GAT
GCC CCA GGC A −3′ and 5′- CTA TGC AGT TGA
TGA AGA TGT CAA A −3′), IFN-γ (5′- TGA ACG
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CTA CAC ACT GCA TCT TGG −3′ and 5′- TGA CTC
CTT TTC CGC TTC CTG AG −3′). PCR conditions
were as follows: initial DNA denaturation at 94 °C for
5 min and 35 rounds of denaturation: 95 °C for 1 min,
annealing (55 °C for IL-2; 60 °C for IL-4, IL-10, and
IFNγ, and 59 °C for GAPDH), and extension 72 °C for
1 min. PCR products were electrophoresed on 1.8%
agarose gels containing 0.5 μg/mL ethidium bromide
and photographed under ultraviolet light.
Determination of cytokine pattern by ELISA
The interleukin 1-beta (IL-1β), IL-6 and TNF-α were
quantified by ELISA in culture supernatants of spleno-
cytes under different conditions of stimulation (120 h),
according to the manufacturer’s protocol. Briefly, 96-
well flat-bottom plates were coated overnight with a
capture antibody at a final concentration of 2 μg/mL,
and then plates were blocked with 10% PBS-FCS,
washed three times, and incubated with the cell culture
supernatant samples or control antigens overnight at
4 °C. After washing, plates were incubated with the re-
spective biotinilated anti-cytokine antibodies (R&D Sys-
tem) at 1 μg/mL for 1 h in the dark. Plates were washed
and Streptavidin-Alkaline Phosphatase at 1:2000 was
added for 30 min in the dark, then washed, and 100 μL of
ABTS (2,2,-azino-bis (3-ethylbenzthiazoline) 6-sulphonic
acid) (Life Technologies) was added as substrate and the
reaction was allowed to proceed for 20 min at room
temperature (RT); the reaction was stopped with 2%
sulphuric acid, and absorbance was read at 415 nm by an
ELISA reader (MultiskanMS, Labsystem).
SDS-PAGE and Western blot analysis
Recombinant protein NS3-DEN3 and/or the total extract
of cells transfected with plasmid pCDNA3/NS3-DEN3
were resolved on 10% SDS-PAGE [24] and visualized by
staining with Coomassie brilliant blue or electrophoret-
ically transferred onto nitrocellulose paper for immuno-
blotting [25, 26]. Blots were incubated with an anti-NS3
antibody at 1:2000 dilution, detected using alkaline
phosphatase-goat anti-mouse IgG (Pierce, Rockford, IL,
USA) diluted at 1:5000, then developed with NBT and
BCIP (Sigma).
Analysis of antibody titers by ELISA and Western blot
ELISA plates were coated overnight at 4 °C with 2 μg/mL
of NS3-DEN3 recombinant protein, in carbonate buffer
(pH 9.6). The plates were washed six times with PBS
containing 0.1% Tween (PBST) and incubated for 2 h at
37 °C with blocking solution (PBS containing 5% skim
Fig. 1 Schematic representation of the immunization schedule. Groups of BALB/c mice (n = 4) received three doses of GST-NS3-DEN3 or GST by
the intraperitoneal (i.p.) route with one week of interval between each dose, or two doses of pcDNA/NS3-DEN3 or pcDNA by the intramuscular
(i.m.) route with two weeks of interval between each dose. Two weeks after the third and second dose respectively, spleen and antiserum
samples were collected from these animals. Splenocytes obtained were used for proliferation assays and determination of cytokines by RT-PCR.
Moreover, the immune serum is used for determination of cytokines by ELISA and to analyze the antibody titer anti-NS3. To control the experiment,
the same procedure was performed in parallel with splenocytes collected from non-vaccinated mice (n = 4)
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milk). Plates were then washed three times with PBST,
three times with PBS, and incubated with 50 μL of
mouse anti-GST-NS3-DEN3 as primary antibodies at
serial dilutions (1:100 – 1:3200) in PBST, and incubated
for 2 h at room temperature. Further washing steps
were conducted and a peroxidase- labeled goat anti-
human IgG antibody (Pierce, Rockford, IL) was added
at 1:8000 dilution in PBS/0.05% Tween 20 and incu-
bated for 1 h at room temperature. After six washes,
100 μL of 2,2,-azino-bis (3-ethylbenzthiazoline)-6-
sulphonic acid (Zymed, South San Francisco, CA) was
added as substrate and the reaction was allowed to
proceed for 20 min at room temperature. The reaction
was stopped with 2% sulfuric acid, and absorbance was
read at 405 nm with an ELISA microplate reader (Mul-
tiscan MS; Labsystems, Vantaa, Finland).
Pooled sera from each group of immunized mice
were used as primary antibodies at serial dilutions
(1:100–1:3200) in TBS-T (150 mM NaCl, 0.05% Tween
20, 2% skim milk, and 10 mM Tris–HCl pH 7.4).
Bound antibodies were detected using alkaline
phosphatase-conjugated goat anti-mouse IgG (Pierce,
Rockford, IL, USA) diluted at 1:5000, then developed
with NBT and BCIP (Sigma).
Statistical analysis
Statistical analysis was performed with GraphPad Prism
(Version 5.0). The results are presented as mean ± stand-
ard deviation. Analysis of variance (ANOVA) followed
by Tukey’s post-hoc test was performed to compare the
mean values among various groups. A p value of <0.05
was considered statistically significant.
Results
Plasmid construction, expression and transfection
A plasmid based on the pCR 2.1-TOPO vector (Invi-
trogen-Life Technologies) was constructed encoding
the NS3pro185 sequence (domain protease of NS3).
The recombinant vector was restricted with Eco RI,
and the fragment was ligated in frame into pGEX-5X-1
(Pharmacia) [11] and pcDNA3 (Invitrogene-Life Tech-
nologies) vectors previously digested with this same
enzyme. Competent Escherichia coli strain DH5-α
cells were transformed with the parental vector
(pGEX-5X-1) as with the recombinant expression vector
(pGEX-NS3-DEN3) (Fig. 2a). The protein production was
induced by addition of isopropyl-β-D-thiogalactoside
(IPTG). After incubation, cells were harvested and purifi-
cation of expressed protein (GST-NS3-DEN3) was per-
formed as previously described [17] (Fig. 2b). DNA
plasmids pcDNA3 and pcDNA3/NS3-DEN3 were isolated
from bacteria by alkaline lysis procedure, and DNA
bands were visualized by ethidium bromide staining
(Fig. 2d). HeLa cells were transiently transfected with
recombinant plasmid (pcDNA3/NS3-DEN3) or control
vector (pcDNA3) using lipofectamine, and harvested
18 h after transfection. Cell extracts of the transfected
cells and untransfected were resolved on 10% SDS-
PAGE (Fig. 2e), and transferred into nitrocellulose
membranes. Recombinant protein was detected with
polyclonal antibodies against the GST-NS3-DEN3 pro-
tein (Fig. 2c and f ).
pcDNA3/NS3-DEN3 induces proliferation but not the
protein NS3-DEN3
The activation of T cell was evaluated by administration
of the antigen in the mouse model. To analyze the ability
to induce proliferation of NS3-DEN3 protein, spleno-
cytes from non-immunized and immunized animals with
the recombinant protein NS3-DEN3 and plasmid
pcDNA3/NS3-DEN were evaluated. The proliferative re-
sponses by spleen cells from normal and immunized
mice (with plasmid and/or recombinant protein) stimu-
lated in vitro with Con A (72 h), GST-NS3-DEN3 10
and 50 μg/mL (120 h) and GST 10 and 50 μg/mL (Data
not shown). Con A induced proliferation of splenic T
cells from normal as well as from immunized mice, no
response was observed when splenocytes from animals
normal or immunized with the recombinant protein
were stimulated with GST-NS3DEN3, however, cells of
mice immunized with the plasmid showed a significant
response towards the stimulation with the recombinant
protein (Fig. 3).
NS3 induced differential expression of genes and
production of cytokines depending on the method
of administration
It is known that pro-inflammatory and anti-inflammatory
cytokines may contribute to the pathogenesis of the infec-
tion and affect the function of all cells types involved in an
immune response. To investigate whether the method of
administration of GST-NS3-DEN3 recombinant protein
alters cytokine expression, RT-PCR analysis was per-
formed in splenocytes from mice immunized with the re-
combinant protein and/or with the plasmid stimulated in
vitro with GST-NS3-DEN3 recombinant protein (Fig. 4a).
When splenocytes were stimulated with GST-NS3-DEN3
recombinant protein, an increase in the expression of
genes for IL-4 and IFN-γ was observed in cells immunized
with the plasmid and stimulated with the protein for 48 h
(Fig. 4a(c), lane 4). However, cells from mice immunized
with the recombinant protein do not express IL-2 or IFN-
γ, but they express IL-4 and IL-10 (Fig. 4a(d), Lane 3 and
4). Furthermore, when the production of pro-
inflammatory cytokines was analyzed in the in the culture
supernatant of splenocytes there was an increase in the
production of IL-1 and TNF-α in splenocytes from mice
immunized with plasmid pcDNA3/NS3-DEN3 and not so
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in splenocytes from mice immunized with GST-NS3-
DEN3 recombinant protein where only an increase in the
production of IL-6 was observed (Fig. 4b).
NS3-DEN3 protein induce the production of antibodies
but not the DNA vaccine pcDNA3/NS3-DEN3
The humoral immune response against GST-NS3-DEN3
was evaluated by immunization of BALB/c mice. The
sera collected from mice 7 days after the last
immunization with recombinant protein or immunized
with the plasmid pcDNA3/NS3-DEN3 were analyzed by
ELISA and WB. The results showed that the antibodies
obtained by immunization with the GST-NS3-DEN3 re-
combinant protein recognize their homologous protein
at a dilution of 1:1600 by ELISA assays (Fig. 5a) and up
to a dilution of 1:3200 by WB (Fig. 5b). However, the
serum obtained from mice immunized with the plasmid
pcDNA3/NS3-DEN3 was not able to recognize GST-
NS3-DEN3 recombinant protein by the methods men-
tioned above (Fig. 5a, b).
Discussion
The NS3 protein is a multifunctional non-structural pro-
tein of flaviviruses implicated in the polyprotein
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Fig. 2 Obtaining recombinants plasmids and recombinant NS3 protein. a Cloning strategy for the NS3 domain protease of dengue virus in the
cloning vector and in prokaryotic and eukaryotic expression vector. b Purification of the recombinant protein NS3DEN3. SDS-PAGE 10% coomassie
blue stained. (M) molecular weight marker. (1) Total cell extract of E. coli DH5α uninduced. (2) Total cell extract of E. coli DH5α induced with IPTG.
(3) recombinant NS3DEN3 protein. The arrow points to the purified protein NS3DEN3 (c) Detection of the recombinant NS3 protein by western
blot with an anti-NS3 antibody. d (M) size marker. (Lane 1) pcDNA3 plasmid linearized with EcoRI. (Lane 2) recombinant plasmid pcDNA3/NS3DEN3
linearized with EcoRI (Lane 3) Fragment release NS3 pro-185. The arrow indicates the fragment released. e HeLa cells transfected. SDS-PAGE
10% coomassie blue stained. (M) molecular weight marker. (1) Total extract untransfected HeLa cells. (2) total extract of HeLa cells transfected
with plasmid pcDNA3/NS3/DEN3. f Detection of NS3 protein by western blot with an anti-NS3 antibody
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processing. The predominance of cytotoxic T cell lym-
phocytes epitopes on the NS3 protein suggests a protect-
ive role of this protein in limiting virus replication. The
NS3 protein is vitally important for the virus since it is
involved in activities such as virus replication, including
protease, NTPase, helicase, and RNA binding and also
capping of the viral genomic RNA [27]. Despite there
are several reports on the structure and function of the
NS3 protein, there are not many studies evaluating the
use of the NS3 protein as an immunogenic antigen. In
this work it was evaluated the immunogenicity and
antigenicity of the recombinant protein GST-NS3-DEN3
and a recombinant plasmid pcDNA3/NS3-DEN3 derived
from NS3 protein. It is known that most of dengue non-
structural proteins expressed in bacterial cells have been
found after cellular disruption in the insoluble fraction
therefore denaturation and refolding processes are re-
quired to recover biologically active proteins [28, 29].
The protease region of NS3 protein was expressed in
E. coli as inclusion bodies, which were subsequently
purified. Moreover, a recombinant plasmid was
obtained. The homogeneity of the purified GST-NS3-
DEN3 recombinant protein as well as transfection effi-
ciency were demonstrated by Western blot.
T cell activation is a critical event for an effective im-
mune response against infection, including the produc-
tion of cytokines [30]. How T cells contribute to the
immune response in dengue disease, has not been clearly
defined yet. The two-effector arms of the immune sys-
tem relevant to protection from viral disease in humans
are neutralizing antibodies and cytotoxic T lymphocytes.
Because T cells do not recognize intact virions, dengue
virus-specific T cells would not be able to provide steril-
izing immunity against viral infection, nevertheless,
DNA and recombinant virus-based vaccines were shown
to induce protective immunity that involved both anti-
body and T cell responses [31, 32]. Our results show that
splenocytes from mice immunized with DNA were able
to respond to in vitro stimulation by the protein, and
not cells from mice immunized with the recombinant
protein. T lymphocytes are not infected by dengue virus,
nevertheless it is possible that exposure to virus and/or
proteins viral may affect their function. T lymphocytes
from DENV-infected individuals are impaired in their
proliferative capacity, although this effect has been at-
tributed to altered function of antigen-presenting cells
rather than to an intrinsic defect on T lymphocytes [33].
Fig. 4 Effect of immunization with pcDNA3/NS3DEN3 and recombinant NS3DEN3 protein on cytokine gene expression in splenocytes of BALB/c
mice. a RT-PCR analysis of cytokines mRNA in splenocytes (a) Normal mice, (b) mice immunized with pcDNA3, (c) mice immunized with pcDNA3/
NS3DEN3, and d) mice immunized with NS3DEN3. (Lane 1) non-stimulated cells, or stimulated (Lane 2) Con A, (Lane 3) NS3DEN3 10 μg/mL,
(Lane 4) NS3DEN3 50 μg/mL. GAPDH was used as control housekeeping gene. b Profile of cytokines induced by NS3DEN3 in splenocytes. Splenocytes
from immunized mice and normal mice were stimulated with the NS3DEN3 protein for 120 h, and cytokines was measured in cells culture
supernatants by ELISA. IL-1 (open bars), IL-6 (full bars), and TNFα (checkered bars). Histograms show values in pg/mL (means ± SD) of three
experiments run in duplicate. *,**,***P < 0.05, 0.001, and 0.0001, respectively, versus unstimulated cells
Fig. 3 Splenic cell proliferation upon stimulation with NS3-DEN3.
The MTT assay was performed with splenocytes from normal mice
or pcDNA3, pcDNA3/NS3DEN3, and NS3DEN3 immunized mice
(cells collected 7 days after the last immunization, three times at
one-week intervals). Non-stimulated (NS) (White bars) or stimulated
with Con A (checkered bars), NS3DEN3 10 μg/mL (Black bars), or
NS3DEN3 50 μg/mL (striped bars). (***P < 0 · 0001)
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The host immune responses have been considered as
the major factor responsible for dengue pathogenesis,
resulting in an altered immune response, which triggers
T cell activation, and the release of cytokines and chem-
ical mediators has been a risk factor in secondary Infec-
tion. During infection occurs a ‘cytokine storm’, defined
as an imbalance between cytokines driving an inflamma-
tion (pro-inflammatory) and those silencing an inflam-
mation (anti-inflammatory). Therefore, serum cytokine
and chemokine levels can serve as a laboratory tool for
predicting severe disease [34]. As it was observed in the
results, DNA immunization induces the synthesis of
cytokines of Th1 profile which can activate T cells,
however, the immunization with the recombinant pro-
tein induces a cytokine profile similar to that observed
during virus infection, where a marked expression of
IL-10 gene and production of IL-1, IL-6, and TNF-α is
observed. Studies show that elevated levels of IL-6, IL-
10, IFN-γ, MIF, and CCL-4 could be used as potential
predictors of severe dengue [35, 36]. Also a model of a
lethal DENV-3 infection, high levels of TNF-α and IL-6
were detected in the serum during the final stages of
the disease [37]. Several lines of evidence indicate that
displacement of viral genotype and host genetic back-
ground are key factors driving the production of a
cytokine storm. Several cytokines are known to induce
apoptosis, a form of cell suicide (cause of hemorrhage),
and/or affect adherents junctions (cause permeability) in
vitro. Whether these cytokines may have such effects in
vivo remains to be established [38]. The development of a
dengue virus (DENV) vaccine has been hampered by the
requirement of simultaneous protection against four dis-
tinct serotypes and the threat that DENV-specific anti-
bodies might either mediate neutralization or, on the
contrary, exacerbate disease through the phenomenon of
antibody-dependent enhancement (ADE) of infection. In
this work, it was observed that immunization with plas-
mid did not induce detectable antibody titers, and not so
immunization with the recombinant protein, this may
be due to endogenous antigen expression within cells
host where DNA immunization can induce an immune
response complete and lasting, with presence of anti-
bodies, although this presence is often weaker than that
obtainable with recombinant proteins. It is thought that
the efficacy of DNA vaccines is mainly due to the anti-
gen mechanisms presentation involved [39]. DNA
immunization has been used as a platform for develop-
ing a tetravalent dengue vaccine in response to the high
priority as a public health problem, animal studies have
succeeded in generating anti-dengue cellular and
humoral immune responses that were protective either
completely or partially against challenge with live den-
gue virus [40]. Finally, in other studies, it has been ob-
served that the DNA vaccines encoding the full-length
NS3 induced a cellular immune response against this
epitope with the production of IFN-γ. Therefore, re-
sults suggest the participation of a cellular immune re-
sponse in the mechanism of protection induced by the
DNA vaccines based on the NS3 protein [41].
Conclusions
If one considers that most vaccine candidates against
DENV focus their attention on the induction of neutral-
izing antibodies against the virus, and that work on cel-
lular immunity are limited, the results obtained in this
study show that administration of pcDNA3/NS3-DEN3
induced a favorable response with the activation of T
lymphocytes with low production of specific antibodies
Fig. 5 Analysis of antibodies against NS3. a Determination of anti-NS3 antibody titer. NS3DEN3 protein was applied to a 96-well ELISA plate, and
anti-NS3 antibodies at different dilutions were added in different wells. Full bars denote the antibody titer obtained by immunization with the
recombinant protein. Open bars denote the antibody titer obtained by immunization with plasmid pcDNA3/NS3DEN3. Pre-immune serum was
used as a negative control. Bound antibody was determined using secondary antibody tagged with HRP. Each bar represents the mean ± standard
error of the mean from three independent experiments. b Analysis of antibodies against NS3 by Western blotting. NS3DEN3 was run in SDS-PAGE,
transferred to nitrocellulose membrane. The membrane was cut into strips, and each strip was developed with primary antibodies at different dilutions
followed by alkaline phosphatase-conjugated secondary antibodies. (a) Serum obtained from mice immunized with the recombinant protein, and (b)
serum obtained from mice immunized with DNA. Lane 1, 1:100; lane 2, 1:200; lane 3, 1:400; lane 4, 1:800; lane 5, 1:1600 and lane 6, 1:3200.
A representative blot from three independent experiments is presented here
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against NS3-DEN3. These results suggest the need to
address the evaluation of the immune response, further
studies will be necessary for the establishment of the
mechanisms involved in the protection induced by the
DNA vaccines based on the NS3 protein.
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